Nanobiotix S.A. (EPA:NANO)

France flag France · Delayed Price · Currency is EUR
2.905
-0.035 (-1.19%)
Apr 24, 2025, 5:35 PM CET
-49.48%
Market Cap 139.37M
Revenue (ttm) -7.19M
Net Income (ttm) -68.13M
Shares Out 47.40M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,992
Average Volume 117,929
Open 2.940
Previous Close 2.940
Day's Range 2.870 - 2.960
52-Week Range 2.620 - 6.970
Beta 1.55
RSI 37.98
Earnings Date Apr 25, 2025

About Nanobiotix

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBT... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 108
Stock Exchange Euronext Paris
Ticker Symbol NANO
Full Company Profile

Financial Performance

Financial Statements

News

Nanobiotix GAAP EPS of -€1.44

Nanobiotix extends cash runway to mid-2026 with €49.7M in reserves, reducing operational cash burn beyond 2026.

21 days ago - Seeking Alpha

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lu...

21 days ago - GlobeNewsWire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST

24 days ago - GlobeNewsWire

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive, nanothe...

27 days ago - GlobeNewsWire

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

PARIS and CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based ...

4 weeks ago - GlobeNewsWire

Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden

On Monday, Nanobiotix SA (NASDAQ: NBTX) announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV , a Johnson & Johnson company (NYSE: JNJ), as part of its financial str...

5 weeks ago - Benzinga

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET

5 weeks ago - GlobeNewsWire

Baillie Gifford's Strategic Acquisition of Nanobiotix SA Shares

Baillie Gifford's Strategic Acquisition of Nanobiotix SA Shares

2 months ago - GuruFocus

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based a...

3 months ago - GlobeNewsWire

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based t...

3 months ago - GlobeNewsWire

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based t...

4 months ago - GlobeNewsWire

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based t...

4 months ago - GlobeNewsWire

Nanobiotix gives Q3 update

Nanobiotix reports €53.2 million in cash and anticipates funding operations through Q4 2025 with current financial projections.

5 months ago - Seeking Alpha

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based appr...

5 months ago - GlobeNewsWire

NANOBIOTIX to Participate in Multiple Investor Conferences in November

~ Guggenheim's Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct...

6 months ago - GlobeNewsWire

Nanobiotix reports 1H results

7 months ago - Seeking Alpha

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based app...

7 months ago - GlobeNewsWire

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based ...

8 months ago - GlobeNewsWire

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appr...

8 months ago - GlobeNewsWire

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appro...

11 months ago - GlobeNewsWire

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

PARIS and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based t...

11 months ago - GlobeNewsWire

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based th...

11 months ago - GlobeNewsWire

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approac...

11 months ago - GlobeNewsWire

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

Nanobiotix S.A. (NASDAQ:NBTX) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call...

1 year ago - Seeking Alpha